Cipla and Qilu ink exclusive deal to sell Keytruda biosimilar in US
Invagen Pharmaceuticals has signed an exclusive US licensing deal with Qilu Pharmaceutical to commercialize QL2107, a Keytruda (pembrolizumab) biosimilar, with Qilu handling development, regulatory work, and supply while Cipla USA drives commercialization. The arrangement underscores Cipla’s strategy to expand its oncology-focused biosimilars portfolio and reduce cancer treatment costs for patients, following multiple collaborations with Chinese manufacturers.
Business · 6 sources · Sep 4, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Dongyi
The Dongyi or Eastern Yi was a collective term for ancient peoples found in Chinese records. The definition of Dongyi varied across the ages, but in most cases referred to inhabitants of eastern China, then later, the Korean peninsula and Japanese Archipelago. Dongyi refers to different group of people in different periods. As such, the name "Yí" was something of a catch-all and was applied to different groups over time.
Everything about Dongyi →